GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » First Wave BioPharma Inc (NAS:FWBI) » Definitions » EV-to-FCF

First Wave BioPharma (First Wave BioPharma) EV-to-FCF : -0.22 (As of May. 03, 2024)


View and export this data going back to 2016. Start your Free Trial

What is First Wave BioPharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, First Wave BioPharma's Enterprise Value is $2.77 Mil. First Wave BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.38 Mil. Therefore, First Wave BioPharma's EV-to-FCF for today is -0.22.

The historical rank and industry rank for First Wave BioPharma's EV-to-FCF or its related term are showing as below:

FWBI' s EV-to-FCF Range Over the Past 10 Years
Min: -1.37   Med: 0   Max: 0.05
Current: -0.22

During the past 10 years, the highest EV-to-FCF of First Wave BioPharma was 0.05. The lowest was -1.37. And the median was 0.00.

FWBI's EV-to-FCF is ranked worse than
100% of 393 companies
in the Biotechnology industry
Industry Median: 4.52 vs FWBI: -0.22

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-03), First Wave BioPharma's stock price is $2.60. First Wave BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-304.477. Therefore, First Wave BioPharma's PE Ratio for today is At Loss.


First Wave BioPharma EV-to-FCF Historical Data

The historical data trend for First Wave BioPharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

First Wave BioPharma EV-to-FCF Chart

First Wave BioPharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.09 -2.20 -0.33 -0.25 -0.29

First Wave BioPharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 -0.16 -0.38 -0.06 -0.29

Competitive Comparison of First Wave BioPharma's EV-to-FCF

For the Biotechnology subindustry, First Wave BioPharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


First Wave BioPharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, First Wave BioPharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where First Wave BioPharma's EV-to-FCF falls into.



First Wave BioPharma EV-to-FCF Calculation

First Wave BioPharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2.765/-12.378
=-0.22

First Wave BioPharma's current Enterprise Value is $2.77 Mil.
First Wave BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


First Wave BioPharma  (NAS:FWBI) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

First Wave BioPharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.60/-304.477
=At Loss

First Wave BioPharma's share price for today is $2.60.
First Wave BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-304.477.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


First Wave BioPharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of First Wave BioPharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


First Wave BioPharma (First Wave BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431
First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
Executives
James Sapirstein director, officer: President and CEO 1517 SAN JACINTO, HOUSTON TX 77002
Sarah Romano officer: Chief Financial Officer 271 WAVERLY OAKS ROAD, WALTHAM MA 02452
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
David Andrew Hoffman director 777 YAMATO ROAD, SUITE 502, BOCA RATON FL 33431
Edward Borkowski director 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Alastair Riddell director C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE, DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217, BROOKLY NY 11226
Vern Lee Schramm director 1300 MORRIS PARK AVE., BIOCHEMISTRY DEPT., BRONX NY 10461
Gregory Oakes director 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
James Pennington officer: CHIEF MEDICAL OFFICER 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Daniel H Schneiderman officer: CHIEF FINANCIAL OFFICER 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Ross Edmund Burke Jr. 10 percent owner C/O JDJ FAMILY OFFICE SERVICES, P.O. BOX 962049, BOSTON MA 02196
Johan M. Spoor director, officer: President and CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Maged Shenouda director 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Pelican Partners Llc 10 percent owner PO BOX 2422, WESTPORT CT 06880

First Wave BioPharma (First Wave BioPharma) Headlines

From GuruFocus

First Wave BioPharma Announces Results of Special Meeting of Stockholders

By Stock market mentor Stock market mentor 01-13-2023

First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio

By Stock market mentor Stock market mentor 01-25-2023

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

By sperokesalga sperokesalga 02-13-2023

First Wave BioPharma to Present at the BIO CEO & Investor Conference

By Stock market mentor Stock market mentor 01-30-2023